Exelixis is a model system biopharmaceutical company focused on the identification and validation of novel screening targets and proteins for the pharmaceutical, diagnostic and agricultural industries. The company is dedicated to the discovery and development of novel small molecule therapeutics for cancer and other serious diseases. The products developed include XL647, XL784, XL880 etc. Exelixis has established strategic corporate alliance with major pharma and biotech companies including Bristol-Myers Squibb, GlaxoSmithKline, Genentech, Wyeth Pharmaceuticals and Sankyo.